Global response to HIV: Treatment as prevention, or treatment for treatment?

Clinical Infectious Diseases

Volumn 59, Issue SUPPL.1, 2014, Pages

  Sigaloff, Kim C E ^a,b   Lange, Joep M A ^a   Montaner, Julio ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c British Columbia Center for Excellence in HIV/AIDS   (Canada)

Author keywords

antiretroviral therapy; HIV 1; resource limited settings; treatment as prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; EPIDEMIC; HEALTH PROGRAM; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; PREGNANT WOMAN; PRIORITY JOURNAL; RESOURCE MANAGEMENT; TREATMENT RESPONSE; DEVELOPING COUNTRY; HIV INFECTIONS;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS;

EID: 84904815407     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu267     Document Type: Article

References (41)

1. Montaner JSG, Hogg R,Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-6. (Pubitemid 44142776)
2. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
3. Cohen MS, Chen YQ, McCauleyM, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
4. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, 2013. Available at: http://aidsinfo.nih. gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 19 January 2014.
5. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
6. World Health Organization. Global update on HIV treatment 2013: results, impact and opportunities. Geneva, Switzerland, 2013. Available at: http://www.who.int/hiv/pub/progressreports/update2013/en/index. html. Accessed 19 January 2014.
7. Shelton JD. HIV/AIDS. ARVs as HIV prevention: a tough road to wide impact. Science 2011; 334:1645-6.
8. Coutsoudis A, Goga A, Desmond C, Barron P, Black V, Coovadia H. Is option B+ the best choice? Lancet 2013; 381:269-71.
9. De Cock KM, El-Sadr WM. When to start ART in Africa-an urgent research priority. N Engl J Med 2013; 368:886-9.
10. Iwuji CC, Orne-Gliemann J, Tanser F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013; 14:230.
11. Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds
12. Fast PE, Price MA, Rida WN, Kamali A, Karita E. WHO's new guidelines for antiretroviral treatment. Lancet 2013; 382:1778-9.
13. World Health Organization. The world health report 2006. Geneva, Switzerland, 2006. Available at: http://www.who.int/whr/2006/whr06-en.pdf. Accessed 19 January 2014.
14. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013; 369:1715-25.
15. Thirumurthy H, Chamie G, Jain V, et al. Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda. AIDS 2013; 27:627-34.
16. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One 2012; 7:e30216.
17. Atun R, Knaul FM, Akachi Y, Frenk J. Innovative financing for health: what is truly innovative? Lancet 2012; 380:2044-9.
18. GAVI Alliance. Funding and finance. Geneva, Switzerland, 2014. Available at: http://www.gavialliance.org/funding/. Accessed 19 January 2014.
19. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 2010; 376:33-40.
20. Kiweewa FM, Wabwire D, Nakibuuka J, et al. Noninferiority of a taskshifting HIV care and treatment model using peer counselors and nurses among Ugandan women initiated on ART: evidence from a randomized trial. J Acquir Immune Defic Syndr 2013; 63:e125-32.
21. Chamie G, Kwarisiima D, Clark TD, et al. Leveraging rapid communitybased HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One 2012; 7:e43400.
22. Uebel KE, Lombard C, Joubert G, et al. Integration of HIV care into primary care in South Africa: effect on survival of patients needing antiretroviral treatment. J Acquir Immune Defic Syndr 2013; 63:e94-100.
23. United Nations Joint Programme on HIV/AIDS. Together we will end AIDS. Geneva, Switzerland, 2012. Available at: https://www. unaids.org/en/resources/ publications/2012/name,72588,en.asp.
24. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24: F11-4.
25. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96. (Pubitemid 44837777)
26. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-65. (Pubitemid 44142768)
27. Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008; 47:421-4. (Pubitemid 352009367)
28. Arnedo-Valero M, Garcia F, Gil C, et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005; 41: 883-90. (Pubitemid 41266758)
29. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of motherto-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6:e1000172.
30. Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health 2010; 15:825-32.
31. Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med 2012; 9:e1001304.
32. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-9.
33. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527-35.
34. Mocroft A, Furrer H, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis 2013; 57:1038-47.
35. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-35.
36. Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T cells. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract 47.
37. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013; 9:e1003211.
38. Luque-Fernandez MA, Van Cutsem G, Goemaere E, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One 2013; 8:e56088.
39. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24:2835-40.
40. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open 2013; 3.
41. Namusobya J, Semitala FC, Amanyire G, et al. High retention in care among HIV-infected patients entering care with CD4 levels <350 cells/μL under routine program conditions in Uganda. Clin Infect Dis 2013; 57:1343-50.